Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kazia Therapeutics ( (KZIA) ) just unveiled an update.
On October 2, 2025, Kazia Therapeutics announced an 86% reduction in tumor burden in a metastatic triple-negative breast cancer (TNBC) patient treated with a combination of paxalisib and immunotherapy. This significant result from a single-patient expanded-access case aligns with the company’s ongoing Phase 1b trial, which is exploring the efficacy of paxalisib in combination with Keytruda and chemotherapy for advanced breast cancer. The announcement underscores Kazia’s commitment to advancing its clinical trials and potentially enhancing treatment options for TNBC patients.
The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. Its lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K/Akt/mTOR pathway, developed for treating multiple forms of cancer. The company is engaged in various clinical trials, including those for glioblastoma and advanced breast cancer, and has received several designations from the FDA for its innovative treatments.
Average Trading Volume: 273,025
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.31M
See more insights into KZIA stock on TipRanks’ Stock Analysis page.